Impax, Purdue strike deal on generic OxyContin

Share this article:

Impax Laboratories announced that it has reached an agreement with Purdue Pharma to settle all outstanding patent litigation surrounding Impax's generic version of the reformulated OxyContin that is now on the market.

In a statement, Impax said will have the right to market a specified number of bottles of its generic OxyContin under the agreement's terms, though that is contingent on the company getting final approval from the FDA on its Abbreviated New Drug Application (ANDA) for the drug. If Impax does not receive final ANDA approval for its generic version, it will still have the right to launch a specified number of bottles of an authorized generic version of OxyContin. In either case, the start date will be Jan. 1, 2016.

IMS Health data put US sales of OxyContin at approximately $2.6 billion for the 12 months ended September 2013.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.